Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Details Work Plan For Healthcare Reforms In 2010

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State Council released April 19 a new work plan for healthcare reform, which details responsibilities of various departments under the State Council and highlights 16 main missions in 2010

You may also be interested in...



Mindray's Q2 Results Disappoint Investors: Weaker China Growth Due To Slowdown In Government Tender

The Chinese device maker remains optimistic about government spending over the long term, as the Chinese government has made no change to its stated three-year health care reform plan or the associated budgets for each category under the plan, exec says.

Mindray's Q2 Results Disappoint Investors: Weaker China Growth Due To Slowdown In Government Tender

The Chinese device maker remains optimistic about government spending over the long term, as the Chinese government has made no change to its stated three-year health care reform plan or the associated budgets for each category under the plan, exec says.

China's Mindray Slides From Weak Government Sales, Increasing Pressure From Multinational Competition

SHANGHAI - U.S.-listed Chinese medical device maker Mindray reported disappointing Q2 results, which made street analysts downgrade full year sales guidance for 2010 to around $700 million, which represents 10 percent growth compared to previous guidance of 17 percent

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel